Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease Treated With Nebulized Arformoterol Following a Respiratory Event

Chronic Obstructive Pulmonary Diseases - United States
doi 10.15326/jcopdf.6.4.2019.0127
Full Text
Abstract

Available in full text

Date
Authors
Publisher

COPD Foundation


Related search